利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.037 秒)

    Crystalline cephalosporin compounds
    5.
    发明授权
    Crystalline cephalosporin compounds 失效
    结晶头孢菌素化合物

    公开(公告)号：US4959469A

    公开(公告)日：1990-09-25

    申请号：US315917

    申请日：1989-02-27

    申请人： Susumu Nakagawa ,  Ryosuke Ushijima ,  Fumio Nakano ,  Koji Yamada ,  Eiichi Mano

    发明人： Susumu Nakagawa ,  Ryosuke Ushijima ,  Fumio Nakano ,  Koji Yamada ,  Eiichi Mano

    IPC分类号： A61K31/545 ,  C07D501/46

    CPC分类号： C07D501/46 ,  A61K31/545 ,  C07D501/18 ,  C07D501/38

    摘要： The present invention relates to stable cyrstalline (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(5,6-dihydroxy-2-methyl-2-isoindolinium)-3-cephem-4-carboxylate sulfate or its hydrate, a process for production of the compound and (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(1-carboxyl-1-methylethoxyimino)acetamido]-3-(5,6-dihydroxy-2-methyl-2-isoindolinium)methyl-3-cephem-4-carboxylate hydrochloride or its hydrate which is a starting material useful for the production of the desired compound of the present invention.

    摘要翻译： 本发明涉及稳定的cyrstalline（6R，7R）-7 - [（Z）-2-（2-氨基噻唑-4-基）-2-（1-羧基-1-甲基乙氧基亚氨基）乙酰氨基] -3-（ 5,6-二羟基-2-甲基-2-异二氢吲哚鎓）-3-头孢烯-4-羧酸甲酯硫酸盐或其水合物，该化合物的制备方法和（6R，7R）-7 - [（Z）-2 - （2-氨基噻唑-4-基）-2-（1-羧基-1-甲基乙氧基亚胺）乙酰胺基] -3-（5,6-二羟基-2-甲基-2-异二氢吲哚鎓）甲基-3-环丙基 - 4-羧酸盐酸盐或其水合物，其为可用于制备本发明所需化合物的原料。

    2-(substituted pyrrolidinylthio)carbapenem derivatives
    6.
    发明授权
    2-(substituted pyrrolidinylthio)carbapenem derivatives 失效
    2-（取代的吡咯烷硫基）碳青霉烯衍生物

    公开(公告)号：US5374720A

    公开(公告)日：1994-12-20

    申请号：US780142

    申请日：1991-10-21

    申请人： Susumu Nakagawa ,  Norikazu Ohtake ,  Fumio Nakano ,  Koji Yamada ,  Ryosuke Ushijima ,  Satoshi Murase ,  Hiroshi Fukatsu

    发明人： Susumu Nakagawa ,  Norikazu Ohtake ,  Fumio Nakano ,  Koji Yamada ,  Ryosuke Ushijima ,  Satoshi Murase ,  Hiroshi Fukatsu

    IPC分类号： C07D477/20 ,  C07D487/04 ,  A61K31/40

    CPC分类号： C07D477/20

    摘要： A compound of the formula: ##STR1## wherein R is a hydrogen atom or a methyl group, R.sup.1 is a hydrogen atom or a negative charge, each of R.sup.2 and R.sup.3 which may be the same or different, is a hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group, a formimidoyl group, an acetoimidoyl group, --COOR.sup.4, --CON(R.sup.5)R.sup.6, --N(R.sup.5)R.sup.6, --CH.sub.2 COOR.sup.4, --CH.sub.2 N(R.sup.5)R.sup.6 or --CH.sub.2 CON(R.sup.5)R.sup.6 (wherein R.sup.4 is a hydrogen atom or a lower alkyl group, each of R.sup.5 and R.sup.6 which may be the same or different, is a hydrogen atom or a lower alkyl group, or R.sup.5 and R.sup.6 form together with the adjacent nitrogen atom a heterocyclic group selected from the group consisting of an aziridinyl group, an azetidinyl group, a pyrrolidinyl group and a piperidyl group), A is .dbd.NR.sup.7, .dbd.N.sup.+ (R.sup.7)R.sup.8, wherein each of R.sup.7 and R.sup.8 which may be the same or different, is a hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group, a formimidoyl group, an acetoimidoyl group, --COOR.sup.4, --CON(R.sup.5)R.sup.6, --N(R.sup.5)R.sup.6, --CH.sub.2 COOR.sup.4, --CH.sub.2 N(R.sup.5)R.sup.6 or --CH.sub.2 CON(R.sup.5)R.sup.6 (wherein R.sup.4, R.sup.5 and R.sup.6 are as defined above), p is an integer of from 0 to 3, and q is an integer of from 1 to 3; or a pharmaceutically acceptable salt or ester thereof.

    摘要翻译： 下式的化合物：其中R是氢原子或甲基，R 1是氢原子或负电荷，R 2和R 3可以相同或不同，为氢原子 ，低级烷基，羟基低级烷基，亚氨基，亚氨酰基，-COOR4，-CON（R5）R6，-N（R5）R6，-CH2COOR4，-CH2N（R5）R6或-CH2CON（ R5）R6（其中R4是氢原子或低级烷基，R5和R6各自可以相同或不同，是氢原子或低级烷基，或R5和R6与相邻的氮原子一起形成） 选自氮丙啶基，氮杂环丁烷基，吡咯烷基和哌啶基的杂环基），A为= NR 7 = N +（R 7）R 8，其中R 7和R 8可以相同或不同， 不同的是氢原子，低级烷基，羟基低级烷基，亚氨基，亚氨代乙酰基，-COOR4，-CON（R5）R6，-N（R5）R6，-CH2COOR4，-CH2N（R5 ）R6或-CH2CON（R5）R6（其中 在R4中，R5和R6如上所定义），p是0-3的整数，q是1至3的整数; 或其药学上可接受的盐或酯。

    2-(substituted pyrrolidinylthio) carbapenem derivatives
    7.
    发明授权
    2-(substituted pyrrolidinylthio) carbapenem derivatives 失效
    2-（取代的吡咯烷硫基）碳青霉烯衍生物

    公开(公告)号：US5373002A

    公开(公告)日：1994-12-13

    申请号：US950717

    申请日：1992-09-25

    申请人： Susumu Nakagawa ,  Norikazu Ohtake ,  Fumio Nakano ,  Koji Yamada ,  Ryosuke Ushijima ,  Satoshi Murase ,  Hiroshi Fukatsu

    发明人： Susumu Nakagawa ,  Norikazu Ohtake ,  Fumio Nakano ,  Koji Yamada ,  Ryosuke Ushijima ,  Satoshi Murase ,  Hiroshi Fukatsu

    IPC分类号： C07D477/20 ,  A01N43/00 ,  A61K31/395 ,  C07D487/04

    CPC分类号： C07D477/20

    摘要： A compound of the formula: ##STR1## wherein R is a hydrogen atom or a methyl group, R.sup.1 is a hydrogen atom or a negative charge, R.sup.2 is a lower alkyl group, a lower alkyl group substituted with a hydroxyl group or --COOR.sup.3 (wherein R.sup.3 is a hydrogen atom or a lower alkyl group), A is .dbd.NH, .dbd.NR.sup.4 or .dbd.N(R.sup.4)R.sup.5 (wherein each of R.sup.4 and R.sup.5 which may be the same or different, is a lower alkyl group or a lower alkyl group substituted with a hydroxyl group), p is an integer of from 0 to 3, and each of q and r which may be the same or different, is an integer of from 0 to 5, provided that q and r are not simultaneously 0 and q +r.ltoreq.6; or a pharmaceutically acceptable salt or ester thereof.

    摘要翻译： 下式的化合物：其中R是氢原子或甲基，R1是氢原子或负电荷，R2是低级烷基，被羟基取代的低级烷基或 -COOR 3（其中R 3为氢原子或低级烷基），A为= NH，= NR 4或= N（R 4）R 5（其中R 4和R 5可以相同或不同，为低级烷基 或被羟基取代的低级烷基），p为0〜3的整数，q和r可以相同或不同，为0〜5的整数，条件是q和r 不同时为0和q + r为6; 或其药学上可接受的盐或酯。